200 related articles for article (PubMed ID: 34319023)
21. [Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition].
Cheng DH; Lu H; Zou XQ
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):771-774. PubMed ID: 29050116
[No Abstract] [Full Text] [Related]
22. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer.
Cheng KK
Eur J Cancer Care (Engl); 2008 May; 17(3):306-11. PubMed ID: 18419635
[TBL] [Abstract][Full Text] [Related]
23. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
Vaishnavi K; Bansal D; Trehan A; Jain R; Attri SV
Pediatr Blood Cancer; 2018 Dec; 65(12):e27241. PubMed ID: 29768710
[TBL] [Abstract][Full Text] [Related]
24. [Influence of thymidylate synthase gene polymorphisms on high-dose methotrexate-related toxicities in childhood acute lymphoblastic leukemia].
Zhu XJ; He XL; Wu YP; Zou RY; Li WL; Zou H; You YL; Liu H; Tian X
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jan; 17(1):11-4. PubMed ID: 25616285
[TBL] [Abstract][Full Text] [Related]
25. [Accidental shortening time of high dose methotrexate infusion: case report and literature review].
Charfi R; Salouage I; Trabelsi S; Zarrouk M; Gaïes E; Jebabli N; Meddeb B; Lakhal M; Klouz A
Ann Biol Clin (Paris); 2013; 71(2):219-22. PubMed ID: 23587592
[TBL] [Abstract][Full Text] [Related]
26. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
Spiegler BJ; Kennedy K; Maze R; Greenberg ML; Weitzman S; Hitzler JK; Nathan PC
J Clin Oncol; 2006 Aug; 24(24):3858-64. PubMed ID: 16921038
[TBL] [Abstract][Full Text] [Related]
27. Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis.
Albertioni F; Rask C; Schroeder H; Peterson C
Anticancer Drugs; 1997 Feb; 8(2):119-24. PubMed ID: 9073308
[TBL] [Abstract][Full Text] [Related]
28. Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.
Liu Y; Yin Y; Sheng Q; Lu X; Wang F; Lin Z; Tian H; Xu A; Zhang J
PLoS One; 2014; 9(1):e82681. PubMed ID: 24404132
[TBL] [Abstract][Full Text] [Related]
29. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.
Bhojwani D; Sabin ND; Pei D; Yang JJ; Khan RB; Panetta JC; Krull KR; Inaba H; Rubnitz JE; Metzger ML; Howard SC; Ribeiro RC; Cheng C; Reddick WE; Jeha S; Sandlund JT; Evans WE; Pui CH; Relling MV
J Clin Oncol; 2014 Mar; 32(9):949-59. PubMed ID: 24550419
[TBL] [Abstract][Full Text] [Related]
30. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
31. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
32. Nephrotoxicity due to intermediate-dose methotrexate without rescue in an obese adolescent with acute lymphoblastic leukemia.
Sauer M; Rydholm N; Piatkowski J; Lewis V; Steiner M
Pediatr Hematol Oncol; 2002 Mar; 19(2):135-40. PubMed ID: 11881788
[TBL] [Abstract][Full Text] [Related]
33. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
[TBL] [Abstract][Full Text] [Related]
34. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Kantar M; Kosova B; Cetingul N; Gumus S; Toroslu E; Zafer N; Topcuoglu N; Aksoylar S; Cinar M; Tetik A; Eroglu Z
Leuk Lymphoma; 2009 Jun; 50(6):912-7. PubMed ID: 19391036
[TBL] [Abstract][Full Text] [Related]
35. Global methylation in relation to methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
Oosterom N; Griffioen PH; den Hoed MAH; Pieters R; de Jonge R; Tissing WJE; van den Heuvel-Eibrink MM; Heil SG
PLoS One; 2018; 13(7):e0199574. PubMed ID: 29985926
[TBL] [Abstract][Full Text] [Related]
36. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.
den Hoed MA; Lopez-Lopez E; te Winkel ML; Tissing W; de Rooij JD; Gutierrez-Camino A; Garcia-Orad A; den Boer E; Pieters R; Pluijm SM; de Jonge R; van den Heuvel-Eibrink MM
Pharmacogenomics J; 2015 Jun; 15(3):248-54. PubMed ID: 25348617
[TBL] [Abstract][Full Text] [Related]
37. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia.
Chae H; Kim M; Choi SH; Kim SK; Lee JW; Chung NG; Cho B; Kim Y
J Chemother; 2020 Sep; 32(5):251-259. PubMed ID: 32431230
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
39. The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia.
Kloos RQH; Pieters R; van den Bos C; van Eijkelenburg NKA; de Jonge R; van der Sluis IM
Leuk Lymphoma; 2019 Dec; 60(12):3002-3010. PubMed ID: 31120351
[TBL] [Abstract][Full Text] [Related]
40. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
